WATERTOWN, Mass.--(BUSINESS WIRE)--Dyno Therapeutics today announced a collaboration with NVIDIA to leverage Dyno’s field-leading artificial intelligence (AI) and in vivo experimentation capabilities, along with the built-to-scale NVIDIA BioNeMo AI-powered drug design platform, to help advance biological sequence design..

马萨诸塞州沃特敦（商业新闻短讯）--Dyno Therapeutics今天宣布与NVIDIA合作，利用Dyno领域领先的人工智能（AI）和体内实验能力，以及按规模构建的NVIDIA BioNeMo AI驱动的药物设计平台，以帮助推进生物序列设计。。

Everything life does is controlled by biological sequences: DNA, RNA, and proteins. The capacity to design these sequences can drastically improve outcomes in healthcare and technology. Over the past decade, Dyno has pioneered an AI-powered approach to sequence design, creating some of the first in vivo-validated biologics using generative AI.

生命所做的一切都受生物序列控制：DNA、RNA和蛋白质。设计这些序列的能力可以大大改善医疗保健和技术的成果。在过去的十年中，Dyno开创了一种人工智能支持的序列设计方法，使用生成人工智能创建了一些首批经过体内验证的生物制剂。

Recently, Dyno’s proprietary generative AI methods yielded optimized capsid products that allow enhanced in vivo delivery of genetic therapies for Dyno’s partners, including the Dyno eCap™ 1 capsid in the eye and the Dyno bCap™ 1 capsid in the brain. Both have been validated through in vivo studies.

最近，Dyno专有的生成AI方法产生了优化的衣壳产品，可以增强Dyno合作伙伴的体内遗传疗法传递，包括眼睛中的Dyno eCap™1衣壳和大脑中的Dyno bCap™1衣壳。两者都已通过体内研究得到验证。

Sequence-design algorithms become much more powerful when trained with appropriately large and diverse data sets and sufficiently fast and versatile computational resources. Dyno believes transformative sequence design capabilities can be brought within reach using its extensive proprietary datasets and the scale NVIDIA’s compute platform enables..

当使用适当的大型和多样化数据集以及足够快速和通用的计算资源进行训练时，序列设计算法变得更加强大。Dyno相信，使用其广泛的专有数据集和NVIDIA的计算平台，可以实现变革性序列设计功能。。

Dyno relies heavily on NVIDIA accelerated computing for its inference and design pipelines. NVIDIA will support the collaboration through its cloud infrastructure, software and the NVIDIA BioNeMo framework. These will enable Dyno to research and deploy advanced machine-learning models at a higher velocity for sequence design.

Dyno的推理和设计流程严重依赖NVIDIA加速计算。NVIDIA将通过其云基础设施、软件和NVIDIA BioNeMo框架支持合作。这些将使Dyno能够以更高的速度研究和部署先进的机器学习模型进行序列设计。

Dyno’s machine learning scientists and engineers will work with NVIDIA AI experts to scale, enhance, and optimize Dyno's AI-powered inference and search algorithms, serving them through NVIDIA NIM microservices and BioNeMo, both part of NVIDIA AI Enterprise..

Dyno的机器学习科学家和工程师将与NVIDIA AI专家合作，通过NVIDIA NIM microservices和BioNeMo（NVIDIA AI Enterprise的两部分）为Dyno的人工智能推理和搜索算法进行扩展、增强和优化。。

“For billions of years, Darwinian evolution has been the world’s most powerful sequence design algorithm, but the resulting gene and genome sequences represent only a slim fraction of what we now know is possible to achieve. For decades, bioengineering progress has advanced primarily through mimicking this process in the lab.

“数十亿年来，达尔文进化论一直是世界上最强大的序列设计算法，但由此产生的基因和基因组序列只代表了我们现在所知道的可能实现的一小部分。几十年来，生物工程的进步主要是通过在实验室中模仿这一过程而取得的。

Dyno has demonstrated that a new route is possible by combining AI with high-throughput molecular experimentation in a self-reinforcing learning loop,” said Eric Kelsic, Ph.D., founder and Chief Executive Officer of Dyno Therapeutics. “Our work with NVIDIA will massively scale and improve this capability so that we can rapidly navigate sequence space at a pace matching revolutionary advances in modern computation, creating transformative medicines that help many more patients.”.

Dyno已经证明，通过将人工智能与高通量分子实验结合在一个自我强化的学习循环中，一种新的途径是可能的，”Dyno Therapeutics创始人兼首席执行官Eric Kelsic博士说。“我们与NVIDIA的合作将大规模扩展并改进这一能力，以便我们能够以与现代计算革命性进步相匹配的速度快速导航序列空间，从而创造出帮助更多患者的变革性药物。”。

“One of the greatest impacts of generative AI is its ability to revolutionize life sciences and healthcare,” said Rory Kelleher, Global Head of Business Development for Life Sciences at NVIDIA. “NVIDIA’s collaboration with Dyno will optimize and scale high-performance biological sequence design, helping to dramatically accelerate the pace of drug discovery and development.”.

NVIDIA生命科学业务发展全球主管Rory Kelleher表示：“生成性人工智能最大的影响之一是它能够彻底改变生命科学和医疗保健。”。“NVIDIA与Dyno的合作将优化和扩展高性能生物序列设计，有助于大大加快药物发现和开发的步伐。”。

All patients can potentially benefit from the ability to design therapies based on biological sequences. As the diversity of life vividly displays the breadth of the sequence-based biological design space, improved sequence-design capabilities have the potential to create myriad new medicines with vast potential for life-changing impact.

所有患者都可能受益于基于生物序列设计疗法的能力。由于生命的多样性生动地展示了基于序列的生物设计空间的广度，改进的序列设计能力有可能创造出无数具有改变生命影响巨大潜力的新药。

For this reason, Dyno was founded to apply advanced sequence design technologies to solve therapeutic challenges. Dyno’s team has been focused over the past decade on solving the challenge of in vivo delivery for genetic therapies by engineering optimized Adeno-associated virus (AAV) capsid sequences, and in doing so became a world leader in machine-guided sequence design and generative AI.

因此，Dyno的成立是为了应用先进的序列设计技术来解决治疗挑战。在过去的十年中，Dyno的团队一直致力于通过工程优化的腺相关病毒（AAV）衣壳序列来解决体内基因治疗的挑战，并因此成为机器引导序列设计和生成AI的世界领导者。

The collaboration is made possible as a result of the insights and learnings generated by the Dyno team, including billions of in vivo sequence-function data points measured across millions of distinct capsid sequences, and the computational revolution being catalyzed by NVIDIA platforms..

由于Dyno团队的见解和学习，包括在数百万个不同衣壳序列中测量的数十亿个体内序列功能数据点，以及NVIDIA平台催化的计算革命，使得合作成为可能。。

Dyno’s team, accelerated by NVIDIA’s full-stack accelerated computing and AI expertise, will develop and apply AI models across numerous research areas including multi-property capsid optimization and design of novel AAV serotypes, while also generalizing these capabilities to a broader range of therapeutically relevant molecules.

Dyno的团队在NVIDIA全栈加速计算和人工智能专业知识的推动下，将在众多研究领域开发和应用人工智能模型，包括多属性衣壳优化和新型AAV血清型的设计，同时还将这些能力推广到更广泛的治疗相关分子。

Dyno’s partners will benefit from the accelerated pace of Dyno’s research and development of new capsid products, as well as from computational capabilities that Dyno may offer to pharmaceutical partners through NVIDIA’s BioNeMo..

Dyno的合作伙伴将受益于Dyno新衣壳产品研发步伐的加快，以及Dyno可能通过NVIDIA的BioNeMo向制药合作伙伴提供的计算能力。。

About Dyno Therapeutics

关于Dyno Therapeutics

Dyno Therapeutics is solving the in vivo gene delivery challenge while partnering with gene therapy developers to maximize patient impact. Dyno’s platform combines AI with high-throughput experimentation to accelerate the design of AAV capsids with properties that significantly outperform current in vivo gene delivery vectors, with the goal of expanding the range of diseases treatable with genetic medicines.

Dyno Therapeutics正在解决体内基因传递的挑战，同时与基因治疗开发人员合作，以最大程度地提高患者的影响。Dyno的平台将人工智能与高通量实验相结合，以加速AAV衣壳的设计，其特性明显优于目前的体内基因传递载体，目的是扩大可用遗传药物治疗的疾病范围。

Dyno has partnered with leading gene therapy developers, including Astellas, Novartis, Roche, and Sarepta, and is broadly open to partnering across therapeutic areas in gene therapy and machine learning. Dyno was founded in 2018 and is located in Watertown, Massachusetts. Visit www.dynotx.com for additional information..

Dyno与领先的基因治疗开发人员合作，包括Astellas，Novartis，Roche和Sarepta，并且在基因治疗和机器学习的治疗领域广泛开放合作。Dyno成立于2018年，位于马萨诸塞州沃特敦。有关更多信息，请访问www.dynotx.com。。